Feature

Early Findings From First Human Study of In Vivo CAR T in Myeloma

The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration...

Share

  • 1

    KLN-1010 is an in vivo CAR T-cell therapy showing promising results for multiple myeloma.

  • 2

    100% of participants achieved early MRD negativity by month one.

  • 3

    Safety profile shows manageable adverse effects, with no high-grade CRS or ICANS.

  • 4

    Therapy eliminates the need for lymphodepletion and apheresis.

  • 5

    Data indicates improved patient outcomes and simplified logistics for treatment.

Original Source(s)

Early Findings From First Human Study of In Vivo CAR T in Myeloma

  • by Caroline Helwick

  • March 20, 2026

Related Content

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling

  • March 18, 2026

  • 9 min
Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine.  

Register Today for Roswell Park’s Upstate New York Hematology & Hematologic Oncology Conference

Register for the Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual meeting, taking place on April 25-26 in Buffalo, NY.

  • by

  • March 13, 2026

  • 1 min